These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25332686)

  • 81. The co-regulators SRC-1 and SMRT are involved in interleukin-6-induced androgen receptor activation.
    Wang Q; Wang H; Ju Q; Ding Z; Ge X; Shi QM; Zhou JL; Zhou XL; Zhang JP; Zhang MR; Yu HM; Xu LC
    Eur Cytokine Netw; 2016 Nov; 27(4):108-113. PubMed ID: 28396297
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.
    Wang Y; Lonard DM; Yu Y; Chow DC; Palzkill TG; O'Malley BW
    Mol Endocrinol; 2011 Dec; 25(12):2041-53. PubMed ID: 22053001
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 84. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
    Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
    Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
    Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
    Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
    Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y
    Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation.
    Su R; Chen L; Jiang Z; Yu M; Zhang W; Ma Z; Ji Y; Shen K; Xin Z; Qi J; Xue W; Wang Q
    Front Oncol; 2022; 12():955166. PubMed ID: 36033483
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Overexpression of steroid receptor coactivator-3 in bone cancers: an in vivo immunohistochemical study with tissue microarray.
    Luo F; Li W; Zhang J; Huang K; Fu J; Xie Z
    Pathol Res Pract; 2013 Dec; 209(12):790-6. PubMed ID: 24134957
    [TBL] [Abstract][Full Text] [Related]  

  • 91. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 92. GRK2 enforces androgen receptor dependence in the prostate and prostate tumors.
    Adler AJ; Mittal P; Hagymasi AT; Menoret A; Shen C; Agliano F; Wright KT; Grady JJ; Kuo CL; Ballesteros E; Claffey KP; Vella AT
    Oncogene; 2020 Mar; 39(11):2424-2436. PubMed ID: 31959897
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.
    Abou-Kheir W; Hynes PG; Martin P; Yin JJ; Liu YN; Seng V; Lake R; Spurrier J; Kelly K
    PLoS One; 2011; 6(10):e26112. PubMed ID: 22022528
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
    Naranjo NM; Kennedy A; Testa A; Verrillo CE; Altieri AD; Kean R; Hooper DC; Yu J; Zhao J; Abinader O; Pickles MW; Hawkins A; Kelly WK; Mitra R; Languino LR
    Cancer Biol Ther; 2024 Dec; 25(1):2364433. PubMed ID: 38926911
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.
    Marhold M; Udovica S; Topakian T; Horak P; Horvat R; Tomasich E; Heller G; Krainer M
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159020
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.
    Valentine H; Aiken W; Morrison B; Zhao Z; Fowle H; Wasserman JS; Thompson E; Chin W; Young M; Clarke S; Gibbs D; Harrison S; McLaughlin W; Kwok T; Jin F; Campbell KS; Horvath A; Thompson R; Lee NH; Zhou Y; Graña X; Ragin C; Badal S
    Cancer Res Commun; 2022 Nov; 2(11):1355-1371. PubMed ID: 36643868
    [TBL] [Abstract][Full Text] [Related]  

  • 98. SRC: marker or actor in prostate cancer aggressiveness.
    Vlaeminck-Guillem V; Gillet G; Rimokh R
    Front Oncol; 2014; 4():222. PubMed ID: 25184116
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs.
    Nikolai BC; Jain P; Cardenas DL; York B; Feng Q; McKenna NJ; Dasgupta S; Lonard DM; O'Malley BW
    Sci Rep; 2021 Feb; 11(1):3441. PubMed ID: 33564037
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Single-cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate.
    Graham MK; Chikarmane R; Wang R; Vaghasia A; Gupta A; Zheng Q; Wodu B; Pan X; Castagna N; Liu J; Meyers J; Skaist A; Wheelan S; Simons BW; Bieberich C; Nelson WG; DeWeese TL; De Marzo AM; Yegnasubramanian S
    Prostate; 2023 Feb; 83(3):286-303. PubMed ID: 36373171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.